News Category
Greenland Mines announces a Q4 2026 spin-off of its biotech division and key milestones in its transition to a critical minerals company, including Na...
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to bolster its financial leadership and advance its proprietary BiTAC te...
Scinai Immunotherapeutics refocuses its R&D portfolio on its NanoAb platform and CDMO business after terminating its license with PinCell, aiming to p...
Onco-Innovations Ltd. strengthens its clinical foundation through manufacturing milestones, IND-enabling activities, and funding, positioning its PNKP...
OS Animal Health, a subsidiary of OS Therapies, is spotlighted at the Moody Capital conference for its promising OST-HER2 immunotherapy targeting cani...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial marks a potential breakthrough in treatin...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a phase 2 trial could herald a new era in MS therapy, add...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Greenland Mines' plan to spin off its biotech division and its completed acquisition of the Sarfartoq rare earths project underscore its strategic piv...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial could revolutionize MS therapy by targeting demyelination rather than immunosuppression, ...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination, could redefine MS therapy by offerin...
The LGL Group’s participation in the Moody Capital conference underscores its strategic focus on critical technologies and disciplined capital allocat...
Interlink Electronics' participation in the Moody Capital conference underscores its strategic growth initiatives and reinforces its position in high-...
As life sciences and AI-driven energy and compute infrastructure see heightened small-cap activity, Moody Capital’s September conference offers a time...
Tonix Pharmaceuticals' promotion of Thomas Englese to Chief Commercial Officer underscores the company's strategic focus on commercializing TONMYA, th...
AcroMeta Group Limited announced a non-binding term sheet with Macro HRD to acquire a stake in Macro-ATCLS and an option for an exclusive Southeast As...
Onco-Innovations has made significant preclinical progress on its PNKP inhibitor ONC010, including high-purity API production and a planned Australian...
VERAXA Biotech's appointment of seasoned financial leader Raju Willener as CFO signals a strategic move to strengthen capital markets expertise and su...
BioVersys, a clinical-stage biopharmaceutical company developing novel antibacterials for multi-drug resistant infections, will present at the H.C. Wa...
OS Therapies' participation in the Moody Capital conference comes as the company anticipates key regulatory decisions and data readouts for its lead c...
A Swiss-led preclinical study reveals that administering immunotherapy before surgery significantly improves glioblastoma treatment outcomes, potentia...
Tonix Pharmaceuticals' participation in the Cantor conference underscores its strategic focus on commercializing TONMYA and advancing its CNS and immu...
NurExone Biologic's participation at the Moody Capital Solutions conference highlights its exosome-based therapies for CNS injuries and its expansion ...
CNS Pharmaceuticals' Chief Business Officer details the company's disciplined approach to building a pipeline in oncology and neurology, emphasizing i...
Hong Kong Science Park's new InnoHK research cluster focuses on sustainable development, energy, advanced manufacturing, and materials, aiming to soli...
Quantum BioPharma Ltd. has been initiated with a 'Buy' rating and an $8.00 price target by Rodman & Renshaw, highlighting the potential of its lead dr...
NanoViricides is progressing its measles drug candidate NV-387 toward Phase II trials, leveraging FDA designations and promising preclinical data, as ...
TransCode Therapeutics announced preclinical results showing TTX-MC138 improves survival in a breast cancer bone metastasis model, supporting its RNA-...
Oragenics provides progress on its Phase IIa trial for mTBI treatment ONP-002 while navigating FDA feedback and NYSE American listing compliance.
Creative Biolabs updates its in vivo CAR-T development portfolio, offering viral and non-viral approaches to support direct immune cell engineering, a...
Lonza's creation of a Chief Commercial Officer role and appointment of Samanta Cimitan underscores its commitment to a unified commercial approach and...
The NMPA's approval of a Phase Ib/II trial for HDP-101 combinations in China marks a significant step in expanding the ADC's potential across earlier ...
A new study published in Critical Care Medicine reveals VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality and renal replac...
Monod Bio's licensing deal with SignalChem Biotech integrates AI-designed proteins into custom assay services, expanding CRO capabilities and advancin...
GeoVax Labs enters a warrant inducement agreement to raise gross proceeds of about $3.6 million, providing working capital to advance its mpox vaccine...
Lakewood-Amedex Biotherapeutics, a clinical-stage biotech developing novel antimicrobials, becomes a B2i Digital Featured Company as it prepares a Pha...
Citius Pharmaceuticals leverages FDA-approved LYMPHIR's commercial launch and a promising late-stage pipeline to address unmet medical needs and drive...
Annovis Bio will provide updates on its Phase 3 Alzheimer's trial and other clinical programs, highlighting upcoming milestones that could significant...
A new study indicates that a personalized mRNA vaccine can prevent melanoma recurrence for years, marking a significant advancement in cancer treatmen...
Creative Biolabs announces a webinar on modeling T cell dysfunction in tumor microenvironments, highlighting the role of metabolic stress in immune ev...
Synthesis Peptides now provides third-party Certificates of Analysis for all 40+ research peptides, using HPLC and mass spectrometry to enhance transp...
A novel T cell therapy offers new hope for patients with recurrent glioblastoma, a condition with limited treatment options and poor prognosis.
VERAXA Biotech and Secarna's early in vitro results show their AOC candidate is more potent than unconjugated oligonucleotides, validating the approac...
VERAXA Biotech's VXA-222 bispecific antibody-drug conjugate program has moved into preclinical development, marking a key milestone and strengthening ...
Scinai Immunotherapeutics' first-half 2026 results show increased revenue and a strategic expansion of its CDMO services, underscoring its dual focus ...
A novel composite scoring system combining biopsy findings and blood test trends identifies that most early liver rejection episodes do not require tr...
VERAXA Biotech's favorable Scientific Advice from Germany's Paul-Ehrlich-Institute de-risks its lead BiTAC-TCE therapy, underscoring the importance of...
VERAXA Biotech's proprietary BiTAC platform and recent pipeline advances underscore its commitment to precision oncology, with potential implications ...
